Moreover, we analyzed the TP53 gene expression and the point mutation in the codon 245 of TP53 gene in cfDNA and its respective tumor tissue to assess its correlation and possible potential as a liquid biomarker in CMTs. This evidence concerns the gene TP53 and neoplasm.